0
0
The European Medicines Agency (EMA) has added Guillain-Barre syndrome to the list of “very rare” adverse reactions to AstraZeneca’s coronavirus vaccine. The likelihood that there is a causal relationship between vaccination with the AstraZeneca vaccine and the occurrence of the nerve disease is “at least reasonable,” according to a statement issued by the EMA yesterday.
The likelihood of developing Guillain-Barre syndrome after AstraZeneca vaccination is very low, the EMA stressed. Fewer than one in 10,000 people are affected, it said. By the end of July, 833 cases of Guillain-Barre syndrome had been detected worldwide – out of about 592 million doses of AstraZeneca vaccine administered.
Guillain-Barre syndrome can cause paralysis as well as breathing problems. In the United States, between 3,000 and 6,000 people contract the rare nerve disease each year. Most patients recover.
The EMA had already included Guillain-Barre syndrome as a “very rare” side effect of Johnson & Johnson’s vaccine in July. The U.S. Food and Drug Administration also warned of an “increased risk” of developing the syndrome after vaccination with the vaccine. However, both agencies stressed that the benefits of the vaccine outweigh the potential risks.
- source: ORF.at/agencies
This post has already been read 689 times!
